BioLight (TASE:BOLT) signed a research collaboration agreement with Alexion, a rare disease unit of AstraZeneca, to explore a potentially ground-breaking technology that utilizes natural tears for the potential...
Search results for - TASE:Bolt
BioLight completes second stage in sale of IOPtima unit
BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) has completed the second stage of the investment in and acquisition in stages of its subsidiary, IOPtima, by Chengdu Kanghong Pharmaceutical Group of China. Under the...
BioLight completes first stage of sale of IOPtima
BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) has completed the first stage of the investment in and acquisition in stages of its subsidiary, IOPtima, by Chengdu Kanghong Pharmaceutical Group of China. Under the first...
BioLight dry eye subsidiary approaching CE Mark filing, U.S. pivotal trial
By Len Zehrs DiagnosTear, the dry eye diagnostic subsidiary of BioLight Life Sciences (TASE:BOLT), hopes to file by the end of 2017 for CE Mark approval in Europe and begin a pivotal trial in the U.S. in mid-2018 with...
BioLight agrees to sell stake in IOPtima
BioLight Life Sciences (TASE:BOLT) and other shareholders of its subsidiary, IOPtima, entered into a binding agreement for the investment and acquisition in stages of IOPtima by Chengdu Kanghong Pharmaceutical Group of...
BioLight posts positive latanoprost insert data
BioLight Life Sciences (TASE:BOLT) announced successful results from its glaucoma insert, VS101, (Eye-D latanoprost) in a Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure (IOP) for...
BioLight TeaRx to be used in DES trial
BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) announced that one of its subsidiaries, DiagnosTear, has signed a services agreement with a pharmaceuticals company to provide analysis services with its TeaRx multi...
BioLight’s CellDetect posts positive results in prostate cancer
BioLight Life Sciences (TASE:BOLT) reported promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology. The study successfully...
BioLight expands portfolio with eye drops for DES
BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry...
Canada clears BioLight’s IOPtiMate system
The Canadian Medical Devices Bureau has approved BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) IOPtiMate system for the treatment of glaucoma, allowing the company to commercialize the surgical system in...
